Everolimus- Versus Biolimus-Eluting Stents in All-Comers (EverBio)

University of Freiburg

Status: Completed

Conditions: Coronary Artery Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01472705

003-REP-CER-FR

Details and patient eligibility

About

This study sought to investigate safety and efficacy of biolimus-eluting stents (BES) with biodegradable polymer as compared with everolimus-eluting stents (EES) with durable polymer through 3 years of follow-up.

Full description

A group of 814 consecutive patients undergoing percutaneous coronary intervention (PCI) was enrolled between 2007 and 2010, of which 527 were treated with EES and 287 with BES implantation. Clinical outcome was compared in 200 pairs using propensity score matching. The primary endpoint was a composite of death, myocardial infarction (MI) and target vessel revascularisation (TVR) at two-year follow-up.

Enrollment: 814 patients

Sex: All

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all patients with at least one BES or EES for de novo stenosis

Exclusion criteria

• patients with at least one non-study stent
• patients with both study stent
• patients with life expectancy < 3 years

Trial design

814 participants in 2 patient groups

everolimus-eluting stents (EES)

Description:

Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.

biolimus-eluting stents (BES)

Description:

Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.